Equity
Additional Paid-In Capital
Boston Scientific Additional Paid-In Capital increased by 0.4% to $21.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.2%, from $21.13B to $21.58B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 1.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 1, 2026
How to read this metric
Increases generally signal successful equity offerings or the vesting of employee stock options.
Detailed definition
The amount of capital received from investors in excess of the par value of common stock. This is a primary component of...
Peer comparison
Varies based on the company's history of equity financing and stock-based compensation intensity.
Metric ID:
equity_additional_paid_in_capital_common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.82B | $19.93B | $19.99B | $20.04B | $20.1B | $20.22B | $20.29B | $20.36B | $20.44B | $20.57B | $20.65B | $20.71B | $20.8B | $20.96B | $21.06B | $21.13B | $21.23B | $21.42B | $21.51B | $21.58B |
| QoQ Change | — | +0.6% | +0.3% | +0.3% | +0.3% | +0.6% | +0.3% | +0.3% | +0.4% | +0.6% | +0.4% | +0.3% | +0.4% | +0.8% | +0.4% | +0.3% | +0.5% | +0.9% | +0.4% | +0.4% |
| YoY Change | — | — | — | — | +1.4% | +1.5% | +1.5% | +1.6% | +1.7% | +1.8% | +1.8% | +1.8% | +1.8% | +1.9% | +2.0% | +2.0% | +2.1% | +2.2% | +2.1% | +2.2% |
Range$19.82B – $21.58B
CAGR+1.8%
Avg YoY Growth+1.8%
Median YoY Growth+1.8%
Current Streak19+ quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Boston Scientific's additional paid-in capital?
- Boston Scientific (BSX) reported additional paid-in capital of $21.58B in Q1 2026.
- How has Boston Scientific's additional paid-in capital changed year-over-year?
- Boston Scientific's additional paid-in capital increased by 2.2% year-over-year, from $21.13B to $21.58B.
- What is the long-term trend for Boston Scientific's additional paid-in capital?
- Over 5 years (2020 to 2025), Boston Scientific's additional paid-in capital has grown at a 1.7% compound annual growth rate (CAGR), from $19.73B to $21.51B.
- What does additional paid-in capital mean?
- Capital received from investors above the nominal par value of the shares.